Anti-HLA-DR Purified

Anti-HLA-DR Purified
Regulatory status
RUO
Antigen
HLA-DR
Clone
L243
Format
Purified
Reactivity
Dog, Non-human primates, Human
Application
IP, WB, FC (QC tested), IHC(F), IHC(P), ICC
Variant
0.1 mg
11-690-C100
In stock

0.025 mg
11-690-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG2a kappa
Specificity
The mouse monoclonal antibody L243 recognizes specifically HLA-DR molecules, both peptide-loaded and empty.
Application
IP, WB, FC (QC tested), IHC(F), IHC(P), ICC
Reactivity
Dog, Non-human primates, Human
Immunogen
Human B lymphocytes
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
11-690 FC
Flow cytometry analysis (surface staining) of HLA-DR in human peripheral blood with anti-HLA-DR (L243) purified / GAM-APC.

Product specific references:

Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M: Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ. 1997 May;8(5):581-8.
PubMed
Muczynski KA, Ekle DM, Coder DM, Anderson SK: Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol. 2003 May;14(5):1336-48.
PubMed
Cantin R, Martin G, Tremblay MJ: A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol. 2001 Dec;82(Pt 12):2979-87.
PubMed
Swiatek-de Lange M, Rist W, Stahl HF, Weith A, Lenter MC: Comment on "MHC class II expression identifies functionally distinct human regulatory T cells". J Immunol. 2008 Mar 15;180(6):3625; author reply 3626.
PubMed
De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E: MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3491-6.
PubMed
Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug;119(8):2143-59.
PubMed
Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL: Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol. 2002 Dec 1;169(11):6149-53.
PubMed
Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W: Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem. 2003 Feb 28;278(9):7099-107.
PubMed
Variant
0.1 mg
11-690-C100
In stock

0.025 mg
11-690-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock